Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
Novartis and Bristol Myers Squibb paused autoimmune CAR-T trials due to safety concerns. Novartis halted eight studies of Rap-cel after three fatal cases, while BMS paused Zola-cel trials due to reversible inflammatory events. Novartis also entered a $3.223B deal with Alteogen for subcutaneous biologics. RedHill acquired Rebyota and Clenpiq from Ferring for $12M upfront. Experts argue for real-world insights in obesity care strategy.
How this was made
The 30-second read
Why it matters
Short‑term stock pressure for NVS and BMY, modest upside for RH; sector‑wide attention on CAR‑T safety.
Market read
Safety pauses could depress biotech equities; acquisition adds pipeline depth for RedHill.
What to watch
Potential for rapid resumption if safety issues are resolved; partnership deals (e.g., Alteogen) may offset short‑term risk.
Background
The article summarizes recent safety‑related trial pauses for two major pharma companies and reports a small acquisition by RedHill Biopharma.
Ticker impact
Novartis halted eight autoimmune CAR‑T trials after three fatal safety events.
downside risk of 3‑5% pending further updates
Trial pauses signal safety issues that can affect investor confidence and upcoming data releases.
Bristol Myers Squibb paused enrollment in its Zola‑cel autoimmune trials due to inflammatory events.
potential 2‑4% dip in the near term
Enrollment halt suggests regulatory scrutiny and could delay pipeline timelines.
Market effects
CAR‑T safety concerns may prompt broader scrutiny of autoimmune cell‑therapy programs.
European and US biotech markets could see modest pressure on similar trial programs.
Highlights regulatory risk in advanced therapy development worldwide.
Counterpoint
The pauses are precautionary and may not materially affect long‑term value; investors could view the safety diligence positively.
Key entities
- CompanyNovartis
Swiss pharma giant halting autoimmune CAR‑T trials.
- CompanyBristol Myers Squibb
U.S. pharma pausing Zola‑cel autoimmune trials.
- CompanyRedHill Biopharma
Acquiring rights to Rebyota and Clenpiq.
